FDA Approves GW Pharma’s CBD Derived Epidiolex to Treat Epilepsy

The United States Food & Drugs Administration (FDA) has officially approved GW Pharmaceuticals’ (NASDAQ: GWPH) Cannabidiol (CBD) derived medication called Epidiolex. The newly approved drug is a oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.

The new CBD derived pharmaceutical will be available to patients through a medical doctors perception for individuals 2 years old or older that suffer from these life crippling diseases.

The approval process has take place over the past few years. The FDA has conducted a series of randomized clinical trials with hundreds of patients suffering from Lennox-Gastaut syndrome and Dravet syndrome. The results found Epidiolex, in conjunction with other medications, to be an efficient solution in the reduction of seizures associated with these conditions.

This announcement should be observed as a huge step forward in the public’s perception of the  cannabinoid known as CBD and officially verifies that the compound contains medicinal benefits. Cannabidiol is non-psychoactive and can be extracted from the cannabis and industrial hemp plants but, has yet to be distinguished away from its schedule-1 drug classification by the FDA.

“The difficult-to-control seizures that patients with Dravet syndrome and Lennox-Gastaut syndrome experience have a profound impact on these patients’ quality of life,” said Billy Dunn, M.D., director of the Division of Neurology Products in the FDA’s Center for Drug Evaluation and Research. “In addition to another important treatment option for Lennox-Gastaut patients, this first-ever approval of a drug specifically for Dravet patients will provide a significant and needed improvement in the therapeutic approach to caring for people with this condition.”

Leave a Comment